KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.

Seth Toback, Anthony M Marchese, Brandy Warren, Sondos Ayman, Senka Zarkovic, Islam ElTantawy, Raburn M Mallory, Matthew Rousculp, Fahed Almarzooqi, Bartlomiej Piechowski-Jozwiak, Maria-Fernanda Bonilla, Agyad Ebrahim Bakkour, Salah Eldin Hussein, Nawal Al Kaabi

Vaccine 42(7) 1777-1784

PMID38365482
PMCID-
DOI10.1016/j.vaccine.2024.02.037
发表日期2024-02-16
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity of NVX-CoV2373 as a heterologous booster compared to BBIBP-CorV when utilized as a homologous booster. Approximately 1000 participants were randomly assigned in a 1:1 ratio to receive a single dose of NVX-CoV2373 or BBIBP-CorV after prior vaccination with 2 or 3 doses of BBIBP-CorV. Solicited adverse events (AEs) were collected for 7 days after vaccination. Unsolicited AEs were collected for 28 days following the booster dose and serious adverse and adverse events of special interest (AESI) were collected throughout the study. Anti-spike IgG and neutralizing antibodies against SARS-CoV-2 were measured at baseline, day 14, day 28, and day 180. The study achieved its primary non-inferiority endpoint and also demonstrated statistically higher neutralization responses when NVX-CoV2373 was utilized as a heterologous booster compared with BBIBP-CorV as a homologous booster. Both vaccines had an acceptably low reactogenicity profile, and no new safety concerns were found. Heterologous boosting with NVX-CoV2373 was a highly immunogenic and safe vaccine regimen in those previously vaccinated with BBIBP-CorV.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。